FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024998069> ?p ?o ?g. }

• W2024998069 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCBrain metastasis from breast cancer incidence is increasing as better control of primary disease leads to longer patient survival. Current therapy for brain metastases is whole brain radiotherapy, stereotactic radiosurgery, or surgical resection. Due to the relative impermeability of the blood brain barrier, not may chemotherapeutics can effectively target these metastases in the brain. Cilengitide, an αVβ3 and αVβ5 inhibitor, is a cyclic RGD containing pentapeptide. Cilengitide has been shown to cross the blood brain barrier and accumulate to appreciable levels in brain tissue in a phase 2 trial in glioblastoma. αVβ3 integrins play a role in angiogenesis, but also are expressed on tumor cells and play a role in proliferation, survival, and invasion. The purpose of these experiments was to examine the role of cilengitide in cell proliferation and survival in a panel of breast cancer cell lines. T-47D, MCF-7, MDA-MB-468, and MDA-MB-231 cell lines were examined. Initially, cells were counted after 1hr of treatment with various cilengitide doses. Next, cells were treated for 4 days with the same cilengitide doses and a proliferation assay (MTS) was performed. These assays showed that at short and long timepoints, cilengitide treatment can have a significant effect on cell viability and proliferation. T-47D cells were particularly sensitive to cilengitide at both short and long timepoints, while MDA-MB-468 cells were particularly resistant. The other cell lines showed an intermediate phenotype. In an attempt to understand the fate of cells following treatment, apoptosis was measured by Annexin V/Propidium Iodide staining and flow cytometry after 48hr treatment with various cilengitide doses. This assay showed increased apoptotic and dead cells, which increased in a dose dependent fashion for all cell lines except MDA-MB-468 cells which again showed no response to cilengitide treatment. As was seen previously, T-47D cells were the most sensitive, followed by MCF-7 cells and then MDA-MB-231 cells. Cells were also examined for Integrin β3 expression by western blot, with target identified in all cell lines. In conclusion, we have observed that cilengitide has both immediate and lasting effects on breast cell line viability and proliferation. Not all cell lines responded equally however, and the reason for these differences is not fully understood. Cilengitide target expression level may play a role in this process, and apoptosis appears to be possible mechanism for cilengitide mediated cell death in these cell lines. Cilengitide appears to be a good candidate for personalized therapy, but a more complete understanding of its effects could identify a patient subpopulation that is most likely to respond favorably to cilengitide.Citation Format: James D. Perry, David Peereboom, Arnab Chakravarti, Tim Lautenschlaeger. Cilengitide induces apoptosis and reduces cell viability in breast cell lines. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-102. doi:10.1158/1538-7445.AM2013-LB-102" @default.
• W2024998069 created "2016-06-24" @default.
• W2024998069 creator A5018381770 @default.
• W2024998069 creator A5026473898 @default.
• W2024998069 creator A5055978367 @default.
• W2024998069 creator A5075490964 @default.
• W2024998069 date "2013-04-15" @default.
• W2024998069 modified "2023-09-26" @default.
• W2024998069 title "Abstract LB-102: Cilengitide induces apoptosis and reduces cell viability in breast cell lines." @default.
• W2024998069 doi "https://doi.org/10.1158/1538-7445.am2013-lb-102" @default.
• W2024998069 hasPublicationYear "2013" @default.
• W2024998069 type Work @default.
• W2024998069 sameAs 2024998069 @default.
• W2024998069 citedByCount "1" @default.
• W2024998069 countsByYear W20249980692015 @default.
• W2024998069 crossrefType "proceedings-article" @default.
• W2024998069 hasAuthorship W2024998069A5018381770 @default.
• W2024998069 hasAuthorship W2024998069A5026473898 @default.
• W2024998069 hasAuthorship W2024998069A5055978367 @default.
• W2024998069 hasAuthorship W2024998069A5075490964 @default.
• W2024998069 hasConcept C121608353 @default.
• W2024998069 hasConcept C126322002 @default.
• W2024998069 hasConcept C142724271 @default.
• W2024998069 hasConcept C143998085 @default.
• W2024998069 hasConcept C190283241 @default.
• W2024998069 hasConcept C2778164965 @default.
• W2024998069 hasConcept C2779013556 @default.
• W2024998069 hasConcept C2780394083 @default.
• W2024998069 hasConcept C502942594 @default.
• W2024998069 hasConcept C530470458 @default.
• W2024998069 hasConcept C53227056 @default.
• W2024998069 hasConcept C54355233 @default.
• W2024998069 hasConcept C55493867 @default.
• W2024998069 hasConcept C62112901 @default.
• W2024998069 hasConcept C71924100 @default.
• W2024998069 hasConcept C81885089 @default.
• W2024998069 hasConcept C86803240 @default.
• W2024998069 hasConceptScore W2024998069C121608353 @default.
• W2024998069 hasConceptScore W2024998069C126322002 @default.
• W2024998069 hasConceptScore W2024998069C142724271 @default.
• W2024998069 hasConceptScore W2024998069C143998085 @default.
• W2024998069 hasConceptScore W2024998069C190283241 @default.
• W2024998069 hasConceptScore W2024998069C2778164965 @default.
• W2024998069 hasConceptScore W2024998069C2779013556 @default.
• W2024998069 hasConceptScore W2024998069C2780394083 @default.
• W2024998069 hasConceptScore W2024998069C502942594 @default.
• W2024998069 hasConceptScore W2024998069C530470458 @default.
• W2024998069 hasConceptScore W2024998069C53227056 @default.
• W2024998069 hasConceptScore W2024998069C54355233 @default.
• W2024998069 hasConceptScore W2024998069C55493867 @default.
• W2024998069 hasConceptScore W2024998069C62112901 @default.
• W2024998069 hasConceptScore W2024998069C71924100 @default.
• W2024998069 hasConceptScore W2024998069C81885089 @default.
• W2024998069 hasConceptScore W2024998069C86803240 @default.
• W2024998069 hasLocation W20249980691 @default.
• W2024998069 hasOpenAccess W2024998069 @default.
• W2024998069 hasPrimaryLocation W20249980691 @default.
• W2024998069 hasRelatedWork W1542412204 @default.
• W2024998069 hasRelatedWork W1766501574 @default.
• W2024998069 hasRelatedWork W1977653352 @default.
• W2024998069 hasRelatedWork W1985367664 @default.
• W2024998069 hasRelatedWork W1990899837 @default.
• W2024998069 hasRelatedWork W2000211955 @default.
• W2024998069 hasRelatedWork W2008908982 @default.
• W2024998069 hasRelatedWork W2022292123 @default.
• W2024998069 hasRelatedWork W2035094376 @default.
• W2024998069 hasRelatedWork W2051139924 @default.
• W2024998069 hasRelatedWork W2090696747 @default.
• W2024998069 hasRelatedWork W2127086398 @default.
• W2024998069 hasRelatedWork W2130527861 @default.
• W2024998069 hasRelatedWork W2314353439 @default.
• W2024998069 hasRelatedWork W2575698999 @default.
• W2024998069 hasRelatedWork W2726668376 @default.
• W2024998069 hasRelatedWork W2809919943 @default.
• W2024998069 hasRelatedWork W2922285587 @default.
• W2024998069 hasRelatedWork W3082058505 @default.
• W2024998069 hasRelatedWork W3112939013 @default.
• W2024998069 isParatext "false" @default.
• W2024998069 isRetracted "false" @default.
• W2024998069 magId "2024998069" @default.
• W2024998069 workType "article" @default.